Talphera, Inc. (TLPH) — 8-K Filings

8-K Filings (15)

• Talphera, Inc. Files 8-K: Director Changes & Shareholder Votes — Oct 24, 2025 Risk: medium
  On October 23, 2025, Talphera, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, the appointment of ce
• Talphera, Inc. Files 8-K on Equity Sales — Oct 22, 2025 Risk: low
  On October 20, 2025, Talphera, Inc. reported on unregistered sales of equity securities and other events. The company, formerly known as AcelRx Pharmaceuticals
• Talphera, Inc. Announces Board Changes and Officer Compensation Updates — Oct 16, 2025 Risk: medium
  On October 14, 2025, Talphera, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announ
• Talphera, Inc. Files 8-K: Material Agreement & Equity Sales — Sep 10, 2025 Risk: medium
  On September 7, 2025, Talphera, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and file
• Talphera, Inc. Faces Delisting Concerns — Jun 5, 2025 Risk: high
  Talphera, Inc. filed an 8-K on June 5, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event
• Talphera, Inc. Files 8-K: Material Agreement, Equity Sales — Apr 2, 2025 Risk: medium
  On March 31, 2025, Talphera, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed f
• Talthera, Inc. Faces Delisting Concerns — Dec 11, 2024 Risk: high
  Talthera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K on December 11, 2024, reporting a notice of delisting or failure to satisfy a continued listi
• Talhera, Inc. Faces Delisting Notice — Nov 29, 2024 Risk: high
  Talhera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K on November 29, 2024, to report a notice of delisting or failure to satisfy a continued listin
• Talphera, Inc. Files 8-K for Material Agreement — Oct 1, 2024 Risk: medium
  On September 30, 2024, Talphera, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits related to this a
• Talheira Appoints Dr. David J. Bearss to Board — Jun 24, 2024 Risk: low
  Talheira, Inc. announced on June 24, 2024, the election of Dr. David J. Bearss to its Board of Directors. Dr. Bearss brings extensive experience in drug develop
• Talphera, Inc. Files 8-K Report — Apr 19, 2024 Risk: low
  On April 19, 2024, Talphera, Inc. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K report. The filing indicates that the company is providing information rel
• Talthera Appoints New CMO, Elects Director — Mar 1, 2024 Risk: low
  Talthera, Inc. announced on February 26, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer and the election of Ms. Sarah E. Empey to its
• TALPHERA Reports Material Agreement, Equity Sales, Financial Condition — Jan 22, 2024
  TALPHERA, INC. (formerly AcelRx Pharmaceuticals Inc.) filed an 8-K on January 22, 2024, reporting events from January 17, 2024. This filing indicates the compan
• TALPHERA Enters Material Definitive Agreement on Jan 12 — Jan 18, 2024
  TALPHERA, INC. filed an 8-K on January 18, 2024, reporting an event that occurred on January 12, 2024, related to an "Entry into a Material Definitive Agreement
• TALPHERA, INC. (TLPH) Files 8-K for Name Change, Nasdaq Listing — Jan 9, 2024
  TALPHERA, INC. (formerly AcelRx Pharmaceuticals, Inc.) filed an 8-K on January 9, 2024, to update its company information, including its new name and trading sy

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX